Published in J Natl Cancer Inst on October 07, 2008
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86
Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol (2015) 2.76
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis (2010) 2.61
IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol (2009) 2.43
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut (2011) 2.38
Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis (2010) 2.35
Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst (2010) 2.29
Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology (2009) 2.13
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96
A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies. Biometrics (2009) 1.79
Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer (2011) 1.74
Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem (2012) 1.69
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66
Semiparametric methods for evaluating risk prediction markers in case-control studies. Biometrika (2009) 1.57
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov (2013) 1.49
The grand challenge to decipher the cancer proteome. Nat Rev Cancer (2010) 1.49
Measures to summarize and compare the predictive capacity of markers. Int J Biostat (2009) 1.49
The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila) (2012) 1.49
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med (2010) 1.47
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One (2010) 1.43
Human Salivary Micro-RNA in Patients with Parotid Salivary Gland Neoplasms. PLoS One (2015) 1.38
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys (2014) 1.30
Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev (2012) 1.30
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev (2010) 1.25
Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst (2009) 1.24
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One (2012) 1.24
The process to discover and develop biomarkers for cancer: a work in progress. J Natl Cancer Inst (2008) 1.19
Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population. Oral Oncol (2010) 1.18
CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One (2012) 1.18
Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genomics (2011) 1.17
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med (2012) 1.16
Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med (2012) 1.16
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Oligosaccharide analysis by mass spectrometry: a review of recent developments. Anal Chem (2013) 1.10
Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci (2012) 1.10
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS (2010) 1.09
Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med (2012) 1.09
IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol (2012) 1.09
Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. Clin Transl Med (2013) 1.09
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol (2014) 1.09
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Semiparametric methods for evaluating the covariate-specific predictiveness of continuous markers in matched case-control studies. J R Stat Soc Ser C Appl Stat (2010) 1.07
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology (2012) 1.06
Ovarian cancer screening--current status, future directions. Gynecol Oncol (2013) 1.06
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med (2014) 1.05
The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem (2012) 1.05
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev (2012) 1.04
Brain investigation and brain conceptualization. Funct Neurol (2013) 1.03
Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol (2014) 1.02
Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies. Am J Epidemiol (2014) 1.00
Evaluating health risk models. Stat Med (2010) 1.00
Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila) (2012) 0.99
Scientific frontiers: emerging technologies for salivary diagnostics. Adv Dent Res (2011) 0.99
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. Springerplus (2013) 0.99
Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. Stat Med (2010) 0.98
Chapter 12: systematic review of prognostic tests. J Gen Intern Med (2012) 0.98
The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics (2012) 0.98
Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol (2011) 0.97
Salivary biomarkers for detection of oral squamous cell carcinoma - current state and recent advances. Curr Oral Health Rep (2014) 0.96
Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer (2012) 0.96
Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics (2012) 0.96
Randomized reverse marker strategy design for prospective biomarker validation. Stat Med (2014) 0.94
Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol (2010) 0.94
Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis (2012) 0.92
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. Int J Hepatol (2010) 0.92
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci (2012) 0.92
Estimating the diagnostic likelihood ratio of a continuous marker. Biostatistics (2010) 0.92
New paradigms in translational science research in cancer biomarkers. Transl Res (2012) 0.92
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer (2013) 0.92
The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma. PLoS One (2012) 0.92
Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol (2013) 0.92
Sample size recalculation in sequential diagnostic trials. Biostatistics (2009) 0.91
Why have protein biomarkers not reached the clinic? Genome Med (2011) 0.91
miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One (2014) 0.91
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst (2015) 0.90
Biomarkers for Early Cancer Detection - Methodological Aspects. Breast Care (Basel) (2010) 0.90
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PLoS One (2012) 0.89
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer (2014) 0.89
Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol (2015) 0.88
Improving biomarker identification with better designs and reporting. Clin Chem (2011) 0.88
External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.87
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One (2011) 0.87
Contrasting two frameworks for ROC analysis of ordinal ratings. Med Decis Making (2010) 0.87
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol (2014) 0.86
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer. Br J Cancer (2012) 0.86
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer (2015) 0.86
Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence. Am J Pathol (2009) 0.86
Biomarkers for incident CKD: a new framework for interpreting the literature. Nat Rev Nephrol (2013) 0.85
Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers (2015) 0.85
Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol (2015) 0.84
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med (1999) 7.32
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
Using a combination of reference tests to assess the accuracy of a new diagnostic test. Stat Med (1999) 4.16
Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol (2005) 3.82
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. Am J Epidemiol (2008) 2.61
Evaluation of diagnostic procedures. BMJ (2002) 2.43
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol (2007) 2.29
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value. Biometrics (2007) 1.88
Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics (2004) 1.81
Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev (2007) 1.25
Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res (2009) 1.13
The winding road towards evidence based diagnoses. J Epidemiol Community Health (2002) 1.10
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol (2004) 12.03
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol (2005) 10.56
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev (2004) 6.24
Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol (2006) 6.03
Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev (2007) 6.00
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72
In vitro fertilization with preimplantation genetic screening. N Engl J Med (2007) 5.26
Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 5.04
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Antibiotic use in relation to the risk of breast cancer. JAMA (2004) 4.28
Is it time to abandon the food frequency questionnaire? Cancer Epidemiol Biomarkers Prev (2005) 4.11
VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol (2004) 3.97
Improving gene set analysis of microarray data by SAM-GS. BMC Bioinformatics (2007) 3.68
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology (2008) 3.35
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA (2003) 3.22
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 3.05
Height as an explanatory factor for sex differences in human cancer. J Natl Cancer Inst (2013) 2.99
Insights into latent class analysis of diagnostic test performance. Biostatistics (2006) 2.92
Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst (2007) 2.87
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA (2008) 2.73
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Early onset of coronary artery disease after prenatal exposure to the Dutch famine. Am J Clin Nutr (2006) 2.71
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 2.69
Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology (2014) 2.67
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst (2004) 2.54
Moderate-intensity exercise reduces the incidence of colds among postmenopausal women. Am J Med (2006) 2.53
Insights into colon cancer etiology via a regularized approach to gene set analysis of GWAS data. Am J Hum Genet (2010) 2.50
Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int J Epidemiol (2010) 2.44
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst (2010) 2.38
Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol (2003) 2.38
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst (2003) 2.29
Occupational risk factors for esophageal and stomach cancers among female textile workers in Shanghai, China. Am J Epidemiol (2006) 2.27
Developing and Evaluating Communication Strategies to Support Informed Decisions and Practice Based on Evidence (DECIDE): protocol and preliminary results. Implement Sci (2013) 2.25
Fine particulate matter and mortality: a comparison of the six cities and American Cancer Society cohorts with a medicare cohort. Epidemiology (2008) 2.25
Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr (2006) 2.25
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Presence of simian virus 40 DNA sequences in human lymphomas. Lancet (2002) 2.21
Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol (2002) 2.19
Comparative evaluation of gene-set analysis methods. BMC Bioinformatics (2007) 2.19
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology (2008) 2.14
Telomere length varies by DNA extraction method: implications for epidemiologic research. Cancer Epidemiol Biomarkers Prev (2013) 2.14
Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res (2004) 2.14
A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol (2009) 2.13
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet (2002) 2.08
Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev (2002) 2.08
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Estimation and Comparison of Receiver Operating Characteristic Curves. Stata J (2009) 2.07
Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J Epidemiol (2003) 2.06
We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med (2008) 2.05
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res (2007) 2.02
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst (2010) 1.99
Screening for colorectal cancer and prostate cancer: challenges for New Zealand. N Z Med J (2014) 1.97
Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause (2004) 1.97
Overinterpretation and misreporting of diagnostic accuracy studies: evidence of "spin". Radiology (2013) 1.96
Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet (2008) 1.96
Measuring the performance of markers for guiding treatment decisions. Ann Intern Med (2011) 1.95
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Characteristics of childhood cancer survivors predicted their successful tracing. J Clin Epidemiol (2004) 1.94
Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev (2002) 1.92
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Folate and cancer--timing is everything. JAMA (2007) 1.88
Differences in proximal serrated polyp detection among endoscopists are associated with variability in withdrawal time. Gastrointest Endosc (2013) 1.87
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Net risk reclassification p values: valid or misleading? J Natl Cancer Inst (2014) 1.86
Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol (2003) 1.86
Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology (2011) 1.83
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
Personalized exposure assessment: promising approaches for human environmental health research. Environ Health Perspect (2005) 1.83